EDIT (Editas Medicine) Cyclically Adjusted Revenue per Share: $0.67 (As of Mar. 2026)


EDIT Editas Medicine Inc EDIT
45 GF Score
Price $3.71
GF Value $1.85
Valuation Significantly Overvalued
! 11 Warning Signs
View Full Analysis

What is Editas Medicine Cyclically Adjusted Revenue per Share?

Editas Medicine EDIT -1.20% 45 Cyclically Adjusted Revenue per Share is $0.67 as of Mar. 2026. GuruFocus rates EDIT with a GF Score™ of 45/100 and a GF Value™ of $1.85 (Significantly Overvalued). The stock has 11 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Editas Medicine's adjusted revenue per share for the three months ended in Mar. 2026 was $0.029. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.67 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Editas Medicine's average Cyclically Adjusted Revenue Growth Rate was 8.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-08), Editas Medicine's current stock price is $3.705. Editas Medicine's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $0.67. Editas Medicine's Cyclically Adjusted PS Ratio of today is 5.53.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Editas Medicine was 9.26. The lowest was 1.66. And the median was 3.92.


Editas Medicine  (NAS:EDIT) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Editas Medicine's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=3.705/0.67
=5.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Editas Medicine was 9.26. The lowest was 1.66. And the median was 3.92.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Editas Medicine Cyclically Adjusted Revenue per Share Related Terms


Editas Medicine Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Editas Medicine's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Editas Medicine Cyclically Adjusted Revenue per Share Chart

Editas Medicine Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.62 0.66

Editas Medicine Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.62 0.63 0.63 0.66 0.67

EDIT vs SGMT, AUTL, FBRX: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Editas Medicine's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Editas Medicine Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Editas Medicine's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Editas Medicine's Cyclically Adjusted PS Ratio falls into.


EDIT
45GF Score
Editas Medicine Inc EDIT
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Editas Medicine Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Editas Medicine's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.029/330.2130*330.2130
=0.029

Current CPI (Mar. 2026) = 330.2130.

Editas Medicine Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.096 241.018 0.132
201609 0.027 241.428 0.037
201612 0.025 241.432 0.034
201703 0.019 243.801 0.026
201706 0.076 244.955 0.102
201709 0.152 246.819 0.203
201712 0.086 246.524 0.115
201803 0.085 249.554 0.112
201806 0.157 251.989 0.206
201809 0.306 252.439 0.400
201812 0.127 251.233 0.167
201903 0.042 254.202 0.055
201906 0.047 256.143 0.061
201909 0.077 256.759 0.099
201912 0.235 256.974 0.302
202003 0.105 258.115 0.134
202006 0.194 257.797 0.248
202009 1.002 260.280 1.271
202012 0.183 260.474 0.232
202103 0.098 264.877 0.122
202106 0.006 271.696 0.007
202109 0.091 274.310 0.110
202112 0.182 278.802 0.216
202203 0.099 287.504 0.114
202206 0.093 296.311 0.104
202209 0.001 296.808 0.001
202212 0.095 296.797 0.106
202303 0.143 301.836 0.156
202306 0.040 305.109 0.043
202309 0.065 307.789 0.070
202312 0.734 306.746 0.790
202403 0.014 312.332 0.015
202406 0.006 314.175 0.006
202409 0.001 315.301 0.001
202412 0.370 315.605 0.387
202503 0.056 319.799 0.058
202506 0.042 322.561 0.043
202509 0.084 324.800 0.085
202512 0.254 324.054 0.259
202603 0.029 330.213 0.029

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $0.67 mean?
Editas Medicine (EDIT) has a Cyclically Adjusted Revenue per Share of $0.67 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Editas Medicine and its competitors.
Is Editas Medicine's Cyclically Adjusted Revenue per Share too high?
Editas Medicine's current Cyclically Adjusted Revenue per Share is $0.67. Overall, Editas Medicine has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Editas Medicine's Cyclically Adjusted Revenue per Share compare to SGMT and AUTL?
Editas Medicine's Cyclically Adjusted Revenue per Share of $0.67 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Editas Medicine and its competitors. Editas Medicine's current Cyclically Adjusted Revenue per Share is $0.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Editas Medicine stock overvalued right now?
Based on GuruFocus' analysis, Editas Medicine (EDIT) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.85, compared to a current price of $3.71 — trading 100.3% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is $0.67. Editas Medicine's overall GF Score™ is 45/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Editas Medicine (EDIT), the current Cyclically Adjusted Revenue per Share is $0.67 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Editas Medicine (EDIT) Overvalued in 2026?

Based on GuruFocus' analysis, Editas Medicine stock appears to be overvalued. The current stock price of $3.71 is trading 100.3% above its estimated GF Value™ of $1.85. GuruFocus considers Editas Medicine to be Significantly Overvalued.

Key valuation signals for EDIT:

  • Cyclically Adjusted Revenue per Share: $0.67
  • GF Value™: $1.85 vs. price of $3.71 (100.3% above fair value)
  • GF Score™: 45/100 with 11 warning signs

No single metric tells the full story. See the EDIT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Editas Medicine Business Description

Other Exchanges 0IFK:UK8EM:Germany
Address 11 Hurley Street, Cambridge, MA, USA, 02141
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
45GF Score

Get the complete analysis for EDIT

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.71
Price
$1.85
GF Value